Last Price$8.511.2%
Market Cap$1,347.5M
DCF value
N/A
Overvalued (DCF value)
(100.0%)
Discount Rate
10.1%
Long-Term Growth Rate
3.0%
Stock quality
6/10
Good
OCUL DCF Model
Free Cash Flow to Firm Model
NOPAT Model
Free Cash Flow to Equity Model
Net Income Model
Millions
Billions
| Dec'20 Actual | Dec'21 Actual | Dec'22 Actual | Dec'23 Actual | Dec'24 Actual | Dec'25 Estimate | Dec'26 Estimate | Dec'27 Estimate | Dec'28 Estimate | Dec'29 Estimate | Dec'30 Estimate | Dec'31 Estimate | Dec'32 Estimate | Dec'33 Estimate | Dec'34 Estimate | Dec'35 Terminal | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 17.4 311.7% | 43.5 150.1% | 51.5 18.3% | 58.4 13.5% | 63.7 9.0% | 71.2 11.7% | 81.8 14.9% | 149.4 82.6% | 359.6 140.6% | 734.9 104.4% | 1,378.0 87.5% | 2,350.8 70.6% | 3,613.1 53.7% | 4,942.7 36.8% | 5,926.2 19.9% | 6,104.0 3.0% |
% margin | (62.8) (361.1%) | (78.0) (179.3%) | (78.7) (152.7%) | (82.4) (141.0%) | (171.8) (269.6%) | (71.2) (100.0%) | (81.8) (100.0%) | (149.4) (100.0%) | (359.6) (100.0%) | (734.9) (100.0%) | (1,378.0) (100.0%) | (2,350.8) (100.0%) | (3,613.1) (100.0%) | (4,942.7) (100.0%) | (5,926.2) (100.0%) | (6,104.0) (100.0%) |
NOPAT % effective tax rate | (64.5) (370.4%) | (128.7) (295.6%) | (70.2) (136.4%) | (82.4) (141.0%) | (171.8) (269.6%) | (71.2) (100.0%) | (81.8) (100.0%) | (149.4) (100.0%) | (359.6) (100.0%) | (734.9) (100.0%) | (1,378.0) (100.0%) | (2,350.8) (100.0%) | (3,613.1) (100.0%) | (4,942.7) (100.0%) | (5,926.2) (100.0%) | (6,104.0) (100.0%) |
% of revenue | 2.8 15.9% | 2.4 5.6% | 2.1 4.1% | 3.0 5.1% | 3.8 5.9% | 3.6 5.0% | 4.1 5.0% | 7.5 5.0% | 18.1 5.0% | 37.1 5.0% | 69.5 5.0% | 118.6 5.0% | 182.4 5.0% | 249.5 5.0% | 299.1 5.0% | 308.1 5.0% |
% of revenue | (0.8) (4.8%) | (1.2) (2.7%) | (3.7) (7.2%) | (6.1) (10.4%) | (1.3) (2.0%) | (4.7) (6.6%) | (5.4) (6.6%) | (9.8) (6.6%) | (23.6) (6.6%) | (48.1) (6.6%) | (90.3) (6.6%) | (154.0) (6.6%) | (236.7) (6.6%) | (323.8) (6.6%) | (388.2) (6.6%) | (399.8) (6.6%) |
% of revenue | 1.2 6.8% | (2.9) (6.7%) | 1.3 2.6% | (7.4) (12.7%) | 0.0 0.0% | (2.4) (3.4%) | (2.7) (3.4%) | (5.0) (3.4%) | (12.1) (3.4%) | (24.6) (3.4%) | (46.2) (3.4%) | (78.8) (3.4%) | (121.2) (3.4%) | (165.8) (3.4%) | (198.7) (3.4%) | (204.7) (3.4%) |
Free Cash Flow to Firm (FCFF) % of revenue | (61.4) (352.5%) | (130.3) (299.5%) | (70.5) (136.9%) | (92.9) (159.0%) | (169.3) (265.7%) | (74.7) (104.9%) | (85.8) (104.9%) | (156.7) (104.9%) | (377.0) (104.9%) | (770.6) (104.9%) | (1,444.9) (104.9%) | (2,465.0) (104.9%) | (3,788.6) (104.9%) | (5,182.7) (104.9%) | (6,214.0) (104.9%) | (6,400.5) (104.9%) |
% of FCFF used in calculation | 80.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||||||
Discount period | 0.50 | 1.50 | 2.50 | 3.50 | 4.50 | 5.50 | 6.50 | 7.50 | 8.50 | 9.50 | ||||||
Discount factor | 0.95 | 0.87 | 0.79 | 0.71 | 0.65 | 0.59 | 0.54 | 0.49 | 0.44 | 0.40 | ||||||
Discounted FCFF (DFCFF) |
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
OCUL DCF Value
DCF Value Calculation
as of Mar 11, 2025
Sum of DFCFF
% share of EV
N/A
30.0%
Terminal Value (TV)
N/A
Discounted TV
% share of EV
N/A
70.0%
Total Debt
75.8M
N/A
Shares outstanding
158.3M
FX rate
N/A
N/A
100% overvalued
Equity Value Bridge
OCUL DCF Financials
Revenue
$63.7M -> $5,926.2M
57.3% CAGR
Operating Income
($171.8M) -> ($5,926.2M)
42.5% CAGR
FCFF
($169.3M) -> ($6,214.0M)
43.4% CAGR
OCUL DCF sensitivity
DCF value
Long-term Terminal growth rate
2.0%
2.5%
3.0%
3.5%
4.0%
WACC
9.0%
$0.0
$0.0
$0.0
$0.0
$0.0
9.5%
$0.0
$0.0
$0.0
$0.0
$0.0
10.1%
$0.0
$0.0
$0.0
$0.0
$0.0
10.5%
$0.0
$0.0
$0.0
$0.0
$0.0
11.0%
$0.0
$0.0
$0.0
$0.0
$0.0
DCF value, undervalued / overvalued
Long-term Terminal growth rate
2.0%
2.5%
3.0%
3.5%
4.0%
WACC
9.0%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
9.5%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
10.1%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
10.5%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
11.0%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
Explore more intrinsic value tools hub for OCUL
Margin of safety
Peter Lynch charts
Ben Graham Fair Value
Earnings Power Value
Relative Value
Earnings growth model
Discount rate
Peter Lynch Fair Value
Intrinsic Value
Reverse DCF
FAQ
What is Ocular Therapeutix, Inc. DCF (discounted cash flow) valuation?
As of Mar 11, 2025, Ocular Therapeutix, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by (100.0%) compared to its current price of around $8.5, using a WACC of 10.1% and growth rates of 3.0%.
What is Ocular Therapeutix, Inc. WACC?
As of Mar 11, 2025, Ocular Therapeutix, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 10.1%.
What is Ocular Therapeutix, Inc. Enterprise Value?
As of Mar 11, 2025, Ocular Therapeutix, Inc.'s Enterprise Value (EV) is approximately $0.0. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.